Literature DB >> 7905041

Protection by lactate of cerebral function during hypoglycaemia.

A Maran1, I Cranston, J Lomas, I Macdonald, S A Amiel.   

Abstract

Severe hypoglycaemia with brain dysfunction limits intensified therapy in patients with insulin-dependent diabetes mellitus, despite evidence that such therapy reduces the risk of chronic complications of the disease. We have investigated the effect of infusing lactate (a potential non-glucose fuel for brain metabolism) on protective, symptomatic neurohumoral responses and on brain function during hypoglycaemia in seven healthy men. Elevation of lactate (within a physiological range) substantially diminished catecholamines, growth hormone, cortisol, and symptomatic responses to hypoglycaemia and lowered the glucose level at which these responses began. Glucagon responses were unaffected. Lactate was also associated with a significant lowering of the glucose level at which brain function deteriorated, suggesting that brain function was protected during the hypoglycaemia. The defect in counter-regulation is similar to that seen in hypoglycaemia-prone diabetic patients. Initiation of the protective responses to hypoglycaemia (except glucagon) can be delayed by supporting metabolism with an alternative metabolic fuel. Cerebral cortical dysfunction of severe hypoglycaemia is also delayed. Our demonstration that higher brain function can be protected during hypoglycaemia may have therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905041     DOI: 10.1016/s0140-6736(94)90876-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  43 in total

Review 1.  Neuroendocrine responses to hypoglycemia.

Authors:  Nolawit Tesfaye; Elizabeth R Seaquist
Journal:  Ann N Y Acad Sci       Date:  2010-10-29       Impact factor: 5.691

2.  Hypertonic lactate solutions: a new horizon for fluid resuscitation?

Authors:  Florian Wagner; Peter Radermacher; Hiroshi Morimatsu
Journal:  Intensive Care Med       Date:  2008-06-18       Impact factor: 17.440

3.  Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain-injured patients.

Authors:  Carole Ichai; Guy Armando; Jean-Christophe Orban; Frederic Berthier; Laurent Rami; Corine Samat-Long; Dominique Grimaud; Xavier Leverve
Journal:  Intensive Care Med       Date:  2008-09-20       Impact factor: 17.440

4.  Recurrent hypoglycemia: boosting the brain's metabolic flexibility.

Authors:  Marina Litvin; Amy L Clark; Simon J Fisher
Journal:  J Clin Invest       Date:  2013-04-01       Impact factor: 14.808

5.  Half-molar sodium-lactate solution has a beneficial effect in patients after coronary artery bypass grafting.

Authors:  Xavier M Leverve; Cindy Boon; Tarmizi Hakim; Maizul Anwar; Erwin Siregar; Iqbal Mustafa
Journal:  Intensive Care Med       Date:  2008-06-18       Impact factor: 17.440

6.  Hypoglycemia: from the laboratory to the clinic.

Authors:  Stephanie A Amiel
Journal:  Diabetes Care       Date:  2009-08       Impact factor: 17.152

7.  Hypoglycemia induced changes in cholinergic receptor expression in the cerebellum of diabetic rats.

Authors:  Sherin Antony; T Peeyush Kumar; Jobin Mathew; T R Anju; C S Paulose
Journal:  J Biomed Sci       Date:  2010-02-05       Impact factor: 8.410

8.  Physiological response to postural change during mild hypoglycaemia in patients with IDDM.

Authors:  A M Robinson; H M Parkin; I A Macdonald; R B Tattersall
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

9.  Enhanced [3H] glutamate binding in the cerebellum of insulin-induced hypoglycaemic and streptozotocin-induced diabetic rats.

Authors:  Anu Joseph; Remya Robinson; C S Paulose
Journal:  Cell Mol Neurobiol       Date:  2007-09-06       Impact factor: 5.046

Review 10.  Mitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategies.

Authors:  Gang Cheng; Rong-hua Kong; Lei-ming Zhang; Jian-ning Zhang
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.